title: Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer.
abstract: Paclitaxel, a class of taxane with microtubule stabilising ability, has remained with platinum based therapy, the standard care for primary ovarian cancer management. A deeper understanding of the immunological basis and other potential mechanisms of action together with new dosing schedules and/or routes of administration may potentiate its clinical benefit. Newer forms of taxanes, with better safety profiles and higher intratumoural cytotoxicity, have yet to demonstrate clinical superiority over the parent compound.
authors.affiliation: Department of Immunology, Monash University, Level 6, The Alfred, Commercial Road, Melbourne, VIC 3181, Australia ; Gynaeoncology Unit, Royal Women's Hospital, 20 Flemington Road, Parkville, Melbourne, VIC 3052, Australia.
authors.forename: Nirmala Chandralega
authors.initials: NC
authors.lastname: Kampan
authors.affiliation: Department of Immunology, Monash University, Level 6, The Alfred, Commercial Road, Melbourne, VIC 3181, Australia.
authors.forename: Mutsa Tatenda
authors.initials: MT
authors.lastname: Madondo
authors.affiliation: Gynaeoncology Unit, Royal Women's Hospital, 20 Flemington Road, Parkville, Melbourne, VIC 3052, Australia ; Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, VIC 3052, Australia.
authors.forename: Orla M
authors.initials: OM
authors.lastname: McNally
authors.affiliation: Gynaeoncology Unit, Royal Women's Hospital, 20 Flemington Road, Parkville, Melbourne, VIC 3052, Australia ; Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, VIC 3052, Australia.
authors.forename: Michael
authors.initials: M
authors.lastname: Quinn
authors.affiliation: Department of Immunology, Monash University, Level 6, The Alfred, Commercial Road, Melbourne, VIC 3181, Australia.
authors.forename: Magdalena
authors.initials: M
authors.lastname: Plebanski
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D002945:Cisplatin / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D017239:Paclitaxel / Q000276:immunology / Q000627:therapeutic use*; D043823:Taxoids / Q000276:immunology / Q000627:therapeutic use*
chemical_list: D043823:Taxoids; D017239:Paclitaxel; D002945:Cisplatin